Thymosin Alpha-1 Results Timeline
What the standard Thymosin Alpha-1 research protocol looks like phase by phase, over a typical 4–12 weeks cycle. This is the escalation schedule from our full dosing protocol, presented as a timeline rather than a table.
Compare:Thymosin Alpha-1 vs TB-500 →
Quick Facts
FREQUENCYTwice weekly
CYCLE LENGTH4–12 weeks
DOSE RANGE1.6–3.2 mg per injection, 2×/week
ROUTESubcutaneous injection
Phase-by-Phase Timeline
Loading / Titration
Standard
Target dose: 1.6 mg 2×/week
Maintenance
Advanced
Target dose: 3.2 mg 2×/week
Reported in Research
- ✓4–12 weeks for immune support; 6–12 months in hepatitis research.
This timeline reflects the structure of the standard Thymosin Alpha-1 research protocol documented on this site — it is not a guarantee of individual outcomes, and timelines vary between research subjects. All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.